Company VERMILLION INC Nasdaq

Equities

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Diagnostics & Testing

Inactive Instrument

End-of-day quote Nasdaq Other stock markets
- ^USD	-

09/07	Aspira Women's Health Inc. announced that it has received $1.910249 million in funding	CI
02/07	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of Powell Speech	MT

Aspira Women's Health Inc. is engaged in the discovery, development, and commercialization of noninvasive, artificial intelligence (AI)-powered tests to aid in the diagnosis of gynecologic diseases. The Company's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus workflow is designed to assess the risk of ovarian malignancy in women planning for surgery and uses two tests, Ova1 as the primary test and Overa as a reflex for Ova1 intermediate range results. Its in-development test pipeline includes OvaMDxSM risk assessment, EndoCheck and EndoMDx, which are designed to expand its ovarian cancer portfolio and address the tremendous need for noninvasive diagnostics for endometriosis. EndoCheck is a noninvasive test designed to identify endometriomas.

USD in Million	2022	Weight	2023	Weight	Delta
Bio-analytic and Diagnostic Services 100.0 %	8	100.0 %	9	100.0 %	+11.85%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	8	100.0 %	9	100.0 %	+11.85%

Managers	Title	Age	Since
Nicole Sandford CEO	Chief Executive Officer	54	22/21/22
Sandra Milligan PSD	President	60	01/04
April J. L. Pradier COO	Chief Operating Officer	-	-
Charles J. Dunton CTO	Chief Tech/Sci/R&D Officer	-	01/18/01
Michelle Snider PRN	Corporate Officer/Principal	-	28/23/28
Diane Powis PRN	Corporate Officer/Principal	-	01/20/01

Members of the board	Title	Age	Since
Ellen Vos BRD	Director/Board Member	68	09/23/09
Stefanie Cavanaugh BRD	Director/Board Member	58	09/23/09
Jannie Herchuk CHM	Chairman	61	09/23/09
Winfred Parnell BRD	Director/Board Member	71	01/23/01
Nicole Sandford CEO	Chief Executive Officer	54	22/21/22
Celeste Fralick BRD	Director/Board Member	68	23/22/23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	12,449,512	7,619,753 ( 61.21 %)	0	61.21 %

Name	Equities	%	Valuation
Jack Schuler 15.41 %	1,918,692	15.41 %	3 M $
Robert Drysdale 10.53 %	1,310,531	10.53 %	2 M $
Armistice Capital LLC 9.294 %	1,157,000	9.294 %	2 M $
H George Schuler 4.931 %	613,855	4.931 %	914 644 $
Eric Schultz 4.370 %	543,998	4.370 %	810 557 $
Vanguard Global Advisers LLC 2.228 %	277,407	2.228 %	413 336 $
B. Riley Wealth Advisors, Inc. 1.007 %	125,374	1.007 %	186 807 $
Nicole Sandford 0.6721 %	83,668	0.6721 %	124 665 $
BlackRock Institutional Trust Co. NA 0.5042 %	62,766	0.5042 %	93 521 $
Geode Capital Management LLC 0.4783 %	59,544	0.4783 %	88 721 $

Aspira Women's Health, Inc.

12117 Bee Caves Road Suite 100

78738, Austin

+512 519 0400

http://www.vermillion.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Diagnostics & Testing

	1st Jan change	Capi.
EXACT SCIENCES CORPORATION	-36.01%	8.68B
GUARDANT HEALTH, INC.	+19.57%	3.86B
IOVANCE BIOTHERAPEUTICS, INC.	+11.93%	2.43B
BGI GENOMICS CO., LTD.	-27.10%	1.84B
VERACYTE, INC.	-14.39%	1.73B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+36.87%	1.16B
CAREDX, INC	+42.42%	842M
SEEGENE, INC.	-8.30%	702M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-13.67%	594M

Bio Diagnostics & Testing